Skip to main content

Table 1 Patient demographic characteristics

From: Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study

Characteristic Group A Group B p-Value
  (n = 42) (n = 126)  
Age (years) 60.5 ± 8.5 60.2 ± 8.4 1.0
Male sex 18 (42.9) 34 (42.9) 1.0
Genotype 1 25 (59.5) 75 (59.5) 1.0
Fatty liver 12 (28.6) 60 (47.6) 0.03
Body weight (kg) 61.7 ± 7.0 61.3 ± 10.3 0.75
Body mass index (kg/m 2 ) 24.9 ± 2.5 24.6 ± 3.2 0.59
Necroinflammatory scores 6.3 ± 2.0 6.0 ± 1.9 0.31
Creatinine (mg/dL) 0.9 ± 0.3 0.9 ± 0.6 0.81
AST (U/L) 99.2 ± 43.8 94.4 ± 62.8 0.65
ALT (U/L) 119.8 ± 62.4 137.1 ± 103.6 0.197
AFP (ng/mL) 45.5 ± 96.4 16.9 ± 42.6 0.08
Albumin (g/dL) 3.8 ± 0.5 4.2 ± 0.4 0.001
Total bilirubin (mg/dL) 1.2 ± 0.5 1.0 ± 0.4 0.03
White blood cell s (×10 3 /μL) 5.5 ± 1.9 5.8 ± 1.7 0.33
Hemoglobin level (g/dL) 13.5 ± 1.8 14.2 ± 1.6 0.03
Platelet count (×10 3 /μL) 129.6 ± 47.3 177.0 ± 54.7 <0.001
HCV RNA (IU/mL) 1.81 ± 2.00 ×106 1.53 ± 6.90 ×106 0.67
Low viral load 14 (33.3) 45 (35.7) 0.78
rs8099917 (TT) 33/40 (82.5) 110/124 (88.7) 0.307
rs12979860 (CC) 34/40 (85) 114/126 (90.5) 0.332
Ribavirin per body weight (mg/kg) 15.7 ± 2.9 16.3 ± 2.7 0.19
  1. HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, α-fetoprotein.
  2. Low viral load, HCV RNA ≤800,000 IU/mL.
  3. mean ± SD; no. (%).
  4. Group A, patients with Ishak fibrosis score 4–6.
  5. Group B, patients with Ishak fibrosis score 0–3.